Journal Information
Vol. 33. Issue 1.
Pages 31-34 (January - February 2022)
Share
Share
Download PDF
More article options
Vol. 33. Issue 1.
Pages 31-34 (January - February 2022)
Case Report
Early atypical malignant transformation of diffuse low-grade astrocytoma: The importance of genotyping
Transformación maligna atípica temprana de astrocitoma difuso de bajo grado: la importancia de genotipificar
Pedro Valente Aguiara,b,
Corresponding author
, Osvaldo Sousaa,b, Roberto Silvac, Rui Vaza,b,d, Paulo Linharesa,b,d
a Department of Neurosurgery, Centro Hospitalar Universitário São João, Oporto, Portugal
b Faculty of Medicine, Oporto University, Portugal
c Department of Anatomical Pathology, Centro Hospitalar Universitário São João, Oporto, Portugal
d Neurosciences Centre, Hospital CUF, Oporto, Portugal
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Additional material (1)
Abstract

Diffuse astrocytoma (WHO grade II) has classically been considered a slow growing tumour, typically affecting young adults, with tendency for late malignant conversion. We describe a case of early atypical malignant transformation of diffuse astrocytoma seventeen months after complete surgical removal, as an intraventricular high-grade glioma (HGG). Retrospective laboratory findings for the presence of IDH 1/2 (isocitrate dehydrogenase) mutations were negative. There is growing evidence that IDH-wildtype (wt) astrocytomas behave more aggressively, therefore identifying IDH-mutation status should be mandatory in order to determine disease prognosis and guide treatment course.

Keywords:
Diffuse astrocytoma
IDH 1/2 mutation
IDH-wildtype
Lower-grade gliomas
Tumour genotype
Resumen

Clásicamente, el astrocitoma difuso (OMS II) se clasificaba como neoplasia de crecimiento lento, afectando a adultos jóvenes y con tendencia para conversión maligna tardía. Reportamos un caso de transformación maligna temprana de astrocitoma difuso de grado bajo 17 meses después de remoción tumoral completa, como glioma intraventricular de grado alto. Un análisis retrospectivo para la presencia de la mutación IDH 1/2 fue negativo. La creciente evidencia demuestra que los astrocitomas IDH-wildtype se comportan de forma más agresiva, así que identificar la mutación IDH debería ser mandatorio para determinar el pronóstico y redireccionar el tratamiento de los astrocitomas.

Palabras clave:
Astrocitoma difuso
Mutación IDH 1/2
IDH-wildtype
Glioma de bajo grado
Genotipificar

Article

These are the options to access the full texts of the publication Neurocirugía (English edition)
Member
Member of the Sociedad Española de Neurocirugía

If it is the first time you have accessed you can obtain your credentials by contacting Elsevier Spain in suscripciones@elsevier.com or by calling our Customer Service at902 88 87 40 if you are calling from Spain or at +34 932 418 800 (from 9 to 18h., GMT + 1) if you are calling outside of Spain.

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option ¿I have forgotten my password¿.

Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Neurocirugía (English edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Neurocirugía (English edition)
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?